Santen Pharmaceutical Co., Ltd.
SNPHF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $558 | $561 | $540 | $571 |
| - Cash | $64 | $85 | $93 | $78 |
| + Debt | $0 | $0 | $34 | $0 |
| Enterprise Value | $495 | $476 | $481 | $493 |
| Revenue | $0 | $69 | $77 | $76 |
| % Growth | -99.3% | -11% | 1.1% | – |
| Gross Profit | $0 | $37 | $46 | $42 |
| % Margin | 54.7% | 54% | 59.7% | 55.3% |
| EBITDA | $0 | $12 | $18 | $16 |
| % Margin | 22.1% | 17.6% | 23.9% | 20.7% |
| Net Income | $0 | $6 | $9 | $9 |
| % Margin | 11.7% | 8.6% | 11.4% | 11.4% |
| EPS Diluted | 0.16 | 17.28 | 25.69 | 25.22 |
| % Growth | -99.1% | -32.7% | 1.9% | – |
| Operating Cash Flow | $0 | $0 | $19 | $14 |
| Capital Expenditures | -$0 | -$0 | -$1 | -$3 |
| Free Cash Flow | $0 | $0 | $18 | $11 |